Hospira (NYSE: HSP) reported earnings on July 31. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Hospira met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share increased. GAAP earnings per share increased.

Margins grew across the board.

Revenue details
 Hospira reported revenue of $1.03 billion. The 11 analysts polled by S&P Capital IQ hoped for revenue of $1.03 billion on the same basis. GAAP reported sales were 0.7% lower than the prior-year quarter's $1.03 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 EPS came in at $0.55. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.51 per share. Non-GAAP EPS of $0.55 for Q2 were 7.8% higher than the prior-year quarter's $0.51 per share. GAAP EPS were $0.20 for Q2 against -$0.02 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Margin details
 For the quarter, gross margin was 31.1%, 260 basis points better than the prior-year quarter. Operating margin was 5.4%, 140 basis points better than the prior-year quarter. Net margin was 3.2%, 340 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $990.8 million. On the bottom line, the average EPS estimate is $0.45.

Next year's average estimate for revenue is $4.06 billion. The average EPS estimate is $2.04.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 138 members out of 167 rating the stock outperform, and 29 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Hospira a green thumbs-up, and nine give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hospira is hold, with an average price target of $33.14.